Join Growin Stock Community!
Beta
Back to LLY.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • Revenue by Segments
  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
cash-and-debt-chart

LLY Cash & Debt

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

As of Q1'26, Eli Lilly's (LLY) cash and short-term investments stood at $5.28B, reflecting a decline from the peak of $9.91B in Q3'25, while total debt reached $43.37B, marking a steady increase from $18.82B in Q2'23. This latest position shows a net debt of approximately $38.09B, indicating ongoing liquidity pressures amid rising obligations. Over the period from Q2'23 to Q1'26, cash and short-term investments exhibited volatility with an overall upward trend, fluctuating between $2.49B and $9.91B before the recent drop, driven by notable surges in Q2'24 ($3.36B), Q3'24 ($3.52B), and Q3'25. In contrast, debt consistently grew from $18.82B to $43.37B, accelerating post-Q4'23 with increments exceeding $4B in several quarters, such as Q1'25 and Q3'25, highlighting expanding leverage that outpaced cash accumulation and may signal increased financing needs for operations or investments.